Lack of neurotoxicity of the vascular targeting agent ZD6126 following repeated i.v. dosing in the rat

Molecular Cancer Therapeutics

Volumn 3, Issue 7, 2004, Pages 783-791

  Horner, Steve A ^a   Gould, Sarah ^a   Noakes, James P ^b   Rattray, Niccola J ^b   Allen, Sandra L ^b   Zotova, Elena ^c   Arezzo, Joseph C ^c  

^a ASTRAZENECA   (United Kingdom)

^b JEALOTT S HILL INTERNATIONAL RESEARCH CENTRE   (United Kingdom)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; N ACETYLCOLCHINOL PHOSPHATE; PACLITAXEL; TUBULIN; TUBULIN INHIBITOR; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG REEXPOSURE; DRUG TARGETING; ELECTROPHYSIOLOGY; FEMALE; FORELIMB; FUNCTIONAL ASSESSMENT; GRIP STRENGTH; HINDLIMB; LOCOMOTION; MALE; MAXIMUM TOLERATED DOSE; MUSCLE STRENGTH; NERVE CONDUCTION; NEUROPATHOLOGY; NEUROTOXICITY; NOCICEPTION; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; TAIL FLICK TEST;

ANIMALS; INJECTIONS, INTRAVENOUS; MALE; MOTOR ACTIVITY; NERVE TISSUE; NERVOUS SYSTEM DISEASES; NEURAL CONDUCTION; ORGANOPHOSPHORUS COMPOUNDS; RATS; RATS, WISTAR;

EID: 4444372391     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Davis PD, Dougherty GJ, Blakey DC, et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002;62:7247-53.
2. Blakey DC, Westwood FR, Walker M, et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002;8:1974-83.
3. Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ. ZD6126: a novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 2002;54:1497-502.
4. Budd GT, Evelhoch J, Langmuir P, Veiero J, Shepherdson K, LoRusso P. A phase I dose-escalation trial of ZD6126 administered as 5 daily doses every 3 weeks to patients with cancer refractory to other treatments. Eur J Cancer Suppl 2003;1:S165.
5. Gadgeel SM, LoRusso PM, Wozniak AJ, Wheeler C. A dose-escalation study of the novel vascular-targeting agent, ZD6126, in patients with solid tumors [abstract]. Proc Am Soc Clin Oncol 2002;21:438.
6. Radema SA, Beerepoot LV, Witteveen EO, et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors [abstract]. Clin Cancer Res 2003;9 Suppl:B34.
7. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-16.
8. Galbraith SM, Rustin GJ, Lodge MA, et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002;20:3826-40.
9. Thorpe PE, Chaplin DJ, Blakey DC. The first international conference on vascular targeting: meeting overview. Cancer Res 2003;63:1144-7.
10. Goto H, Yano S, Zhang H, et al. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Res 2002;62:3711-5.
11. Siemann DW, Rojiani AM. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002;54:1512-7.
12. Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002;53:164-71.
13. Siemann DW, Shi W. B7 Antivascular combination therapy, using the antiangiogenic agent ZD6474 and the vascular-targeting agent ZD6126 in human tumor xenograft models [abstract]. Clin Cancer Res 2003; 9 Suppl:B7.
14. Guy SP, Ashton S, Hughes G, Westwood R, Blakey DC, Ryan AJ. B13 gefitinib (Iressa, ZD1839) enhances the activity of the novel vascular-targeting agent ZD6126 in human colorectal cancer and non-small cell lung cancer (NSCLC) xenograft models [abstract]. Clin Cancer Res 2003; 9 Suppl:B13.
15. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol 2002;249:9-17.
16. Hilkens PH, ven den Bent MJ. Chemotherapy-induced peripheral neuropathy. J Peripher Nerv Syst 1997;2:350-61.
17. Aley KO, Reichling DB, Levine JD. Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans. Neuroscience 1996;73:259-65.
18. Mimura Y, Kato H, Eguchi K, Ogawa T. Schedule dependency of paclitaxel-induced neuropathy in mice: a morphological study. Neurotoxicology 2000;21:513-20.
19. Polomano RC, Mannes AJ, Clark US, Bennett GJ. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 2001;94:293-304.
20. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F. Description of a short-term Taxol-induced nociceptive neuropathy in rats. Brain Res 2000;887:239-49.
21. Dina OA, Chen X, Reichling D, Levine JD. Role of protein kinase Cepsilon and protein kinase A in a model of paclitaxel-induced painful peripheral neuropathy in the rat. Neuroscience 2001;108:507-15.
22. Cavaletti G, Cavalletti E, Montaguti P, Oggioni N, De Negri O, Tredici G. Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology 1997;18:137-45.
23. Cliffer KD, Siuciak JA, Carson SR, et al. Physiological characterization of Taxol-induced large-fiber sensory neuropathy in the rat. Ann Neurol 1998;43:46-55.
24. Tanner KD, Reichling DE, Levine JD. Nociceptor hyper-responsiveness during vincristine-induced painful peripheral neuropathy in the rat. J Neurosci 1998;18:6480-91.
25. Cavaletti G, Tredici G, Braga M, Tazzari S. Experimental peripheral neuropathy induced in adult rats by repeated intraperitoneal administration of taxol. Exp Neurol 1995;133:64-72.
26. Topp KS, Tanner KD, Levine JD. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol 2000;424:563-76.
27. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999;17:1061-70.
28. Ogawa T, Mimura Y, Isowa K, et al. An antimicrotubule agent, TZT-1027, does not induce neuropathologic alterations which are detected after administration of vincristine or paclitaxel in animal models. Toxicol Lett 2001;121:97-106.
29. Bacher G, Nickel B, Emig P, et al. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res 2001;61:392-9.
30. Kruczynski A, Hill BT. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol 2001;40:159-73.
31. Abbott NJ. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat 2002;200:629-38.
32. Allt G, Lawrenson JG. The blood-nerve barrier: enzymes, transporters and receptors - a comparison with the blood-brain barrier. Brain Res Bull 2000;52:1-12.
33. Bart J, Groen HJ, Hendrikse NH, van der Graaf WT, Vaalburg W, de Vries EG. The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev 2000;26:449-62.
34. Ziske CG, Schottker B, Gorschluter M, et al. Acute transient encephalopathy after paclitaxel infusion: report of three cases. Ann Oncol 2002;13:629-31.
35. Chen YL, Jan KM, Lin HS, Chien S. Ultrastructural studies on macromolecular permeability in relation to endothelial cell turnover. Atherosclerosis 1995;118:89-104.
36. Schmelzer J, Low PA. Electrophysiological studies on the effect of age on caudal nerve of the rat. Exp Neurol 1987;96:612-20.
37. Hamers FP, Pette C, Neijt JP, Gispen WH. The ACTH-(4-9) analog, ORG 2766, prevents taxol-induced neuropathy in rats. Eur J Pharmacol 1993;233:177-8.
38. Apfel SC, Lipton RB, Arezzo JC, Kessler JA. Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 1991;29:87-90.
39. Campana WM, Eskeland N, Calcutt NA, Misasi R, Myers RR, O'Brien JS. Prosaptide prevents paclitaxel neurotoxicity. Neurotoxicology 1998; 19:237-44.
40. Berger T, Malayeri R, Doppelbauer A, et al. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer 1997;33:1393-9.
41. Vainionpaa L, Kovala T, Tolonen U, Lanning M. Vincristine therapy for children with acute lymphoblastic leukemia impairs conduction in the entire peripheral nerve. Pediatr Neurol 1995;13:314-8.
42. DelProposto Z, LoRusso P, Latif Z, et al. MRI evaluation of the effects of the vascular-targeting agent ZD6126 on tumor vasculature [abstract]. Proc Am Soc Clin Oncol 2002;21:440.
43. Radema SA, Beerepoot LV, Witteveen PO, Gebbink MF, Wheeler C, Voest EE. Clinical evaluation of the novel vascular-targeting agent, ZD6126: assessment of toxicity and surrogate markers of vascular damage [abstract]. Proc Am Soc Clin Oncol 2002;21:439.
44. Rustin GJ, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003;21:2815-22.
45. Jameson MB, Thompson PI, Baguley BC, et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003;88:1844-50.
46. Lobert S, Ingram JW, Hill BT, Correia JJ. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol 1998;53: 908-15.